We are live on ! Find out more
6CM

683 Capital Management Portfolio holdings

AUM $2.04B
1-Year Est. Return 94.26%
This Fund
S&P 500
This Quarter Est. Return
+21.35%
1 Year Est. Return
+94.26%
3 Year Est. Return
+310.51%
5 Year Est. Return
+306.13%
10 Year Est. Return
+3,783.92%
AUM
$2.04B
AUM Growth
+$120M
Cap. Flow
-$149M
Cap. Flow %
-7.33%
Top 10 Hldgs %
47.27%
Holding
257
New
21
Increased
32
Reduced
47
Closed
104

Top Buys

Rank Stock Value
1
U icon
Unity
U
+$16.4M
2
TRAX
First Tracks Biotherapeutics
TRAX
+$14M
3
SE icon
Sea Limited
SE
+$11.9M
4
NU icon
Nu Holdings
NU
+$10.1M
5
GOSS icon
Gossamer Bio
GOSS
+$9.54M

Top Sells

Rank Stock Value
1
ASTH icon
Astrana Health
ASTH
+$17.6M
2
LLY icon
Eli Lilly
LLY
+$15.3M
3
GXO icon
GXO Logistics
GXO
+$14.8M
4
FOLD
Amicus Therapeutics
FOLD
+$11.2M
5
APLS
Apellis Pharmaceuticals
APLS
+$10.1M

Sector Composition

Rank Sector Weight
1 Miscellaneous 48.9%
2 Healthcare 24.5%
3 Financials 7.3%
4 Consumer Discretionary 7.28%
5 Technology 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABEO icon
151
Abeona Therapeutics
ABEO
$331M
– –
-770,000
Closed -$3.45M
ACHV icon
152
Achieve Life Sciences
ACHV
$776M
– –
-200,000
Closed -$588K
ADMA icon
153
PUT
ADMA Biologics
ADMA
$2.12B
– –
-50,000
Closed -$451K
AGEN
154
Agenus
AGEN
$309M
– –
-114,336
Closed -$382K
AMPY icon
155
Amplify Energy
AMPY
$204M
– –
-160,000
Closed -$998K
AMTX icon
156
Aemetis
AMTX
$132M
– –
-235,557
Closed -$751K
APLS
157
DELISTED
Apellis Pharmaceuticals
APLS
– –
-250,000
Closed -$10.1M
APYX icon
158
Apyx Medical
APYX
$128M
– –
-20,000
Closed -$73.8K
ARMP icon
159
Armata Pharmaceuticals
ARMP
$201M
– –
-137,000
Closed -$1.4M
ASMB icon
160
Assembly Biosciences
ASMB
$669M
– –
-27,863
Closed -$773K
AVTX icon
161
Avalo Therapeutics
AVTX
$977M
– –
-56,850
Closed -$849K
AXTI icon
162
AXT Inc
AXTI
$4.52B
– –
-17,000
Closed -$969K
BDTX icon
163
Black Diamond Therapeutics
BDTX
$121M
– –
-247,958
Closed -$528K
BKNG icon
164
Booking.com
BKNG
$130B
– –
-55,000
Closed -$9.26M
CABA icon
165
Cabaletta Bio
CABA
$493M
– –
-225,000
Closed -$605K
CACI icon
166
CACI
CACI
$13.4B
– –
-4,000
Closed -$2.18M
CAMP icon
167
CAMP4 Therapeutics
CAMP
$272M
– –
-108,000
Closed -$476K
CCCC icon
168
C4 Therapeutics
CCCC
$423M
– –
-300,000
Closed -$789K
CCLD icon
169
CareCloud
CCLD
$89.7M
– –
-159,761
Closed -$583K
CCOI icon
170
CALL
Cogent Communications
CCOI
$478M
– –
-500,000
Closed -$9.42M
CCOI icon
171
Cogent Communications
CCOI
$478M
– –
-450,300
Closed -$8.48M
CHCI icon
172
Comstock Holding Companies
CHCI
$212M
– –
-19,500
Closed -$369K
COYA icon
173
Coya Therapeutics
COYA
$108M
– –
-70,000
Closed -$276K
CRBP icon
174
Corbus Pharmaceuticals
CRBP
$171M
– –
-85,543
Closed -$803K
CZR icon
175
Caesars Entertainment
CZR
$6.05B
– –
-150,000
Closed -$3.96M
5 6
7
8 9

Similar funds

SFI
Siemens Fonds Invest Munich, Germany $2.04B AUM 40.78% 1-Year Est. Return
UF
Univest Financial Souderton, Pennsylvania $2.04B AUM 33.06% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
C
Certuity North Palm Beach, Florida $2.03B AUM 88.59% 1-Year Est. Return
EF
Evanson Financial Mclean, Virginia $2.04B AUM
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $2.03B AUM 17.65% 1-Year Est. Return

683 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, 683 Capital Management held 257 positions worth $2.04B, up 6.3% from $1.92B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

683 Capital Management withdrew a net $149M in Q2 2026, closing 104 positions and reducing 47 holdings. Its most notable exit was Eli Lilly, an estimated $15.3M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, up from 47% a quarter earlier, followed by Healthcare and Financials.

Against the trend, 683 Capital Management opened a new position in Unity worth $17.6M.

  • 683 Capital Management's largest Q2 2026 buy was Unity: 615,000 shares worth $17.6M.
  • 683 Capital Management added most to Gossamer Bio in Q2 2026, an estimated $9.54M increase.
  • 683 Capital Management's biggest Q2 2026 reduction was Astrana Health, cutting an estimated $17.6M.
  • 683 Capital Management fully exited Eli Lilly in Q2 2026, selling an estimated $15.3M.
  • 683 Capital Management's ten largest holdings make up 47% of its $2.04B portfolio in Q2 2026.
  • 683 Capital Management opened 21 new positions and closed 104 in Q2 2026.
  • 683 Capital Management's portfolio value rose 6.3% quarter-over-quarter to $2.04B.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.